Manufacturing development and clinical production of NKG2D Chimeric Antigen Receptor-expressing T cells for autologous adoptive cell therapy

BACKGROUND: Adoptive cell therapy employing natural killer group 2D (NKG2D) chimeric antigen receptor (CAR)-modified T cells has demonstrated preclinical efficacy in several model systems, including hematological and solid tumors. We present comprehensive data on manufacturing development and clinic...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cytotherapy
Päätekijät: Murad, Joana M., Baumeister, Susanne H., Werner, Lillian, Daley, Heather, Negre, Helene, Reder, Jake, Sentman, Charles L., Gilham, David, Lehmann, Frederic, Snykers, Sarah, Sentman, Marie-Louise, Wade, Terri, Schmucker, Adam, Fanger, Michael W., Dranoff, Glenn, Ritz, Jerome, Nikiforow, Sarah
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127861/
https://ncbi.nlm.nih.gov/pubmed/30180944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2018.05.001
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia